share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Officer Dubovsky Filip

SEC announcement ·  Mar 12 20:49
Summary by Moomoo AI
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
On March 10, 2024, Novavax's President of R&D, Filip Dubovsky, completed a stock transaction involving the company's common stock. Dubovsky sold 2,597 shares at a price of $5.45 per share, resulting in a total transaction value of $14,153.65. This sale was part of a transaction coded as 'F', typically indicating a payment of exercise price or tax liability by delivering or withholding securities. On the same day, Dubovsky also acquired 5,376 shares through an exercise or conversion of derivative security, coded as 'M'. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 66,613 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more